Insider Trading Alert - CPIX, ORA And SLAB Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, May 28, 2015, 91 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $529.45 to $86,394,898.20.

Highlighted Stocks Traded by Insiders:

Cumberland Pharmaceuticals (CPIX) - FREE Research Report

Lawrence Thomas R, who is Director at Cumberland Pharmaceuticals, sold 6,000 shares at $6.88 on May 28, 2015. Following this transaction, the Director owned 54,381 shares meaning that the stake was reduced by 9.94% with the 6,000-share transaction.

The shares most recently traded at $6.84, down $0.04, or 0.58% since the insider transaction. Historical insider transactions for Cumberland Pharmaceuticals go as follows:

  • 4-Week # shares sold: 6,000
  • 12-Week # shares sold: 6,000
  • 24-Week # shares sold: 6,000

The average volume for Cumberland Pharmaceuticals has been 32,200 shares per day over the past 30 days. Cumberland Pharmaceuticals has a market cap of $113.4 million and is part of the health care sector and drugs industry. Shares are up 14.21% year-to-date as of the close of trading on Thursday.

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for the hospital acute care and gastroenterology markets in the United States. The company has a P/E ratio of 56.2. Currently, there are no analysts who rate Cumberland Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CPIX - FREE

TheStreet Quant Ratings rates Cumberland Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and feeble growth in the company's earnings per share. Get the full Cumberland Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Ormat Technologies (ORA) - FREE Research Report

Bronicki Investments Ltd., who is Shareholder at Ormat Technologies, sold 240,000 shares at $37.24 on May 28, 2015. Following this transaction, the Shareholder owned 4.1 million shares meaning that the stake was reduced by 5.59% with the 240,000-share transaction.

The shares most recently traded at $37.18, down $0.06, or 0.16% since the insider transaction.

The average volume for Ormat Technologies has been 178,400 shares per day over the past 30 days. Ormat Technologies has a market cap of $1.8 billion and is part of the utilities sector and utilities industry. Shares are up 36.79% year-to-date as of the close of trading on Thursday.

Ormat Technologies, Inc. engages in the geothermal and recovered energy power business worldwide. The company operates in two segments, Electricity and Product. The stock currently has a dividend yield of 0.64%. The company has a P/E ratio of 40.9. Currently, there is 1 analyst who rates Ormat Technologies a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on ORA - FREE

TheStreet Quant Ratings rates Ormat Technologies as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, expanding profit margins and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and disappointing return on equity. Get the full Ormat Technologies Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Silicon Laboratories (SLAB) - FREE Research Report

Sooch Navdeep S, who is Director at Silicon Laboratories, sold 30,000 shares at $54.37 on May 28, 2015. Following this transaction, the Director owned 669,749 shares meaning that the stake was reduced by 4.29% with the 30,000-share transaction.

The shares most recently traded at $55.63, up $1.26, or 2.27% since the insider transaction. Historical insider transactions for Silicon Laboratories go as follows:

  • 4-Week # shares bought: 1,400
  • 4-Week # shares sold: 3,665
  • 12-Week # shares bought: 1,400
  • 12-Week # shares sold: 7,987
  • 24-Week # shares bought: 1,400
  • 24-Week # shares sold: 37,987

The average volume for Silicon Laboratories has been 281,100 shares per day over the past 30 days. Silicon Laboratories has a market cap of $2.3 billion and is part of the technology sector and electronics industry. Shares are up 15.29% year-to-date as of the close of trading on Thursday.

Silicon Laboratories Inc., a fabless semiconductor company, designs, develops, and markets mixed-signal analog intensive integrated circuits (ICs). The company has a P/E ratio of 65.0. Currently, there are 6 analysts who rate Silicon Laboratories a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SLAB - FREE

TheStreet Quant Ratings rates Silicon Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Silicon Laboratories Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing